Exact Sciences schedules third-quarter 2018 earnings call
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Exact Sciences (EXAS) Defended at Leerink
October 10, 2018 12:27 PM EDTLeerink Partners analyst Puneet Souda weighed in on Exact Sciences (NASDAQ: EXAS) saying the liquidy biopsy CRC screening tests are worth watching but are far from commercialization.
The analyst reiterated an Outperform and price target of $90.
For an analyst ratings... More



